鉴定(生物学)
亚型
一致性
医学
临床试验
计算生物学
计算机科学
败血症
子群分析
个性化医疗
梅德林
重症监护医学
生物信息学
分层(种子)
精密医学
危险分层
差速器(机械装置)
系统生物学
治疗效果
可扩展性
转化研究
数据挖掘
全身炎症反应综合征
复制
感染性休克
机器学习
生存分析
病人护理
作者
Zhongheng Zhang,Lin Chen,Hongjie Shen,Jing Wang,Jie Yang,Suibi Yang,Weimin Zhang,Xuandong Jiang,Xiaojun Wu,Xianglin Meng,Fengzhi Zhao,Wan‐Jie Gu,Haiyan Yin,Lihui Wang,Yuetian Yu,Lingxia Cheng,Ping Xu,D. W. T. Fei,Huijie Yu,Xuning Shen
标识
DOI:10.1038/s41467-025-65271-4
摘要
Sepsis, a syndrome of life-threatening organ dysfunction caused by dysregulated host responses to infection, exhibits profound pathobiological heterogeneity, hindering the development of effective therapies. Current subtyping approaches, often reliant on single-omics data or unsupervised clustering, yield poorly reproducible and therapeutically misaligned classifications. Here, we introduce a goal-directed subgroup identification (GD-SI) framework that optimizes patient stratification for differential treatment responses, integrating longitudinal multi-omics data (transcriptomic, proteomic, metabolomic, phenomic) from 1327 subjects across 43 hospitals. While supervised multi-omics integration frameworks (e.g., DIABLO) effectively capture shared biological signals, our approach anchors subgroup discovery directly to treatment-effect optimization. This strategy achieves substantial cross-omic concordance and, crucially, generalizes to predict differential treatment response across international critical care databases. Patients stratified by GD-SI-derived benefit scores for restrictive versus liberal fluid resuscitation exhibited marked survival differences, with similar advantages observed for ulinastatin immunomodulation. External validations in MIMIC-IV and ZiGongDB confirm prognostic generalizability. This framework reconciles biological heterogeneity with clinical actionability, offering a scalable infrastructure for precision trial design and personalized sepsis management. Our findings underscore the translational potential of omics-driven, goal-directed stratification to overcome decades of therapeutic stagnation in critical care.
科研通智能强力驱动
Strongly Powered by AbleSci AI